NOVABRIDGE BIOSCIENCES

Novabridge Biosciences shares rise 3.01 % as Phase 1b givastomig data shows 80 % objective response rates, driving optimism for a fast‑track Phase 3 launch.

Novabridge Biosciences shares drop 3.9% as the company advances its antibody‑based oncology therapy to early‑phase trials, marking a key regulatory milestone.

Novabridge Biosciences shares slipped 3.86% to $1.37, amid a 24‑hour dip for peers; discover key market data and why I‑Mab Biopharma targets unmet cancer and autoimmune needs.

Novabridge Biosciences (NBP) surges 9.6% as insider buying ramps up—find out how its biotech breakthroughs and market volatility could shape investor decisions.